TCGA-62-A471-01A-12R-A24H-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.500
- OXIDATIVE_PHOSPHORYLATION+0.490
- XENOBIOTIC_METABOLISM+0.370
- INTERFERON_ALPHA_RESPONSE+0.350
- E2F_TARGETS+0.320
- G2M_CHECKPOINT+0.270
- GLYCOLYSIS+0.270
- FATTY_ACID_METABOLISM+0.250
- MTORC1_SIGNALING+0.220
- ESTROGEN_RESPONSE_LATE+0.210
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- UV_RESPONSE_DN-0.330
- ALLOGRAFT_REJECTION-0.280
- INFLAMMATORY_RESPONSE-0.250
- APICAL_JUNCTION-0.240
- TGF_BETA_SIGNALING-0.240
- ANGIOGENESIS-0.220
- HEDGEHOG_SIGNALING-0.190
- PROTEIN_SECRETION-0.180
- KRAS_SIGNALING_UP-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-01419 | — | cohortA1 | 0.821 |
| 2 | TCGA-A8-A09E-01A-11R-A00Z-07 | — | B | 0.792 |
| 3 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.788 |
| 4 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.777 |
| 5 | TCGA-UU-A93S-01A-21R-A41B-07 | — | C | 0.765 |
| 6 | MNG713 | — | — | 0.764 |
| 7 | SRR8518230 | — | E | 0.761 |
| 8 | SRR25043614 | — | — | 0.761 |
| 9 | SRR975598 | — | — | 0.759 |
| 10 | b2b4cc41-5760-4463-bcde-16115ceb12c2 | — | — | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.370 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |